India to Dominican Republic: Ampicillin Export Trade Route

To import finished pharmaceutical formulations containing Ampicillin into the Dominican Republic, compliance with the Ministry of Public Health's regulations is mandatory. The General Directorate of Medicines, Food, and Health Products (DIGEMAPS) oversees the registration and importation of pharmaceutical products.

Sanitary Registration: Each pharmaceutical product must obtain a Sanitary Registration ("Registro Sanitario") from DIGEMAPS before importation. This registration is valid for five years and is essential for legal distribution within the country.

All documentation must be in Spanish or accompanied by certified translations.

Dossier Format: While the Common Technical Document (CTD) format is widely recognized, the Dominican Republic may have specific requirements. It's advisable to consult DIGEMAPS for the preferred dossier format.

Approval Timelines: The approval process typically takes between 60 to 90 days from the date of application submission.

Product Registration Fees: As of the latest available information, the assessment of import applications is free of charge.

GMP Inspection Requirements: Foreign manufacturing facilities must provide evidence of Good Manufacturing Practice (GMP) compliance. DIGEMAPS may require GMP certificates issued by recognized authorities. In some cases, on-site inspections by Dominican authorities may be conducted to verify compliance.

Indian exporters of Ampicillin formulations must adhere to stringent GMP standards to access the Dominican market.

GMP Certifications: Manufacturers must possess GMP certificates recognized by international health authorities. These certificates should be issued by competent regulatory bodies and demonstrate compliance with international manufacturing standards.

Approved Indian Facilities: Specific information regarding currently approved Indian manufacturing facilities for Ampicillin formulations in the Dominican Republic is not publicly disclosed. Exporters should ensure their facilities meet all regulatory requirements and maintain open communication with DIGEMAPS.

Recent Inspections and Regulatory Actions: As of March 2026, there have been no publicly reported inspections or regulatory actions by DIGEMAPS against Indian pharmaceutical companies exporting to the Dominican Republic. However, exporters are advised to stay informed about any regulatory updates or changes.

In the past 18 months, the Dominican Republic has implemented regulatory changes affecting pharmaceutical imports:

September 2025: DIGEMAPS adopted Resolution No. 0017-2025, approving the Technical Regulation on the marketing of Cosmetic, Personal Hygiene, and Household Products. While primarily focused on cosmetics, this regulation underscores the country's commitment to stringent regulatory controls, which may influence pharmaceutical product oversight.

October 2025: The Dominican Republic notified the World Trade Organization (WTO) of its import licensing procedures for pharmaceuticals, cosmetics, personal hygiene products, and domestic hygiene products. This notification provides transparency regarding the country's import requirements and procedures.

Exporters should monitor these developments to ensure compliance with evolving regulatory requirements in the Dominican Republic.

The Dominican Republic's pharmaceutical imports totaled approximately $1.01 billion in 2024. While specific data on Ampicillin formulations is limited, antibiotics represent a significant segment of the pharmaceutical market. The demand for Ampicillin formulations is driven by factors such as the prevalence of bacterial infections, healthcare spending, and the country's commitment to universal health coverage. In 2024, the Dominican Republic imported pharmaceutical products worth $159.39 million from the United States, indicating a reliance on imports to meet domestic demand. Domestic pharmaceutical manufacturing exists but is supplemented by imports to fulfill the healthcare needs of the population.

Pharmaceutical products under HS code 30041020 are subject to a 0% MFN import duty rate in the Dominican Republic. Additionally, the country imposes a Value Added Tax (VAT) on imports; however, pharmaceutical products are typically exempt from VAT to ensure affordability and accessibility. The Dominican Republic is a member of the Central America-Dominican Republic Free Trade Agreement (CAFTA-DR), which provides preferential tariff treatment for member countries. However, India is not a party to this agreement, so imports from India do not benefit from CAFTA-DR preferences. There are no known anti-dumping duties specifically targeting pharmaceutical imports from India.

In 2024, the United States was the leading supplier of pharmaceutical products to the Dominican Republic, with imports valued at approximately $159.39 million. India was the second-largest supplier, followed by Germany, Switzerland, and Mexico. India's share of the Dominican Republic's total pharmaceutical imports indicates a strong presence in the market. While specific pricing data for Ampicillin formulations is not readily available, Indian pharmaceutical products are generally known for their cost competitiveness compared to those from the European Union and other regions. This pricing advantage, combined with India's robust pharmaceutical manufacturing capabilities, positions Indian exporters favorably in the Dominican Republic's pharmaceutical market.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug supply by volume as of 2024. The country's pharmaceutical industry is valued at over $50 billion, with exports exceeding $25 billion in the 2022-2023 financial year.

The nation boasts a robust manufacturing infrastructure, with over 650 U.S. FDA-approved facilities and more than 2,000 WHO-GMP-certified plants as of 2024. This extensive network enables large-scale production of finished dosage forms, including Ampicillin formulations such as tablets, capsules, syrups, and injections.

India's cost-effective production capabilities are driven by economies of scale, a skilled workforce, and favorable regulatory policies. These factors contribute to the competitive pricing of Ampicillin formulations without compromising quality. The country's commitment to maintaining high manufacturing standards is evident in the significant reduction of regulatory non-compliance instances over the past decade.

When comparing Ampicillin formulation exports, India offers a compelling balance of cost and quality. While specific per-unit pricing data for 2024 is not readily available, India's pharmaceutical exports have been growing at a rate of 9%, nearly double the global average, indicating competitive pricing strategies.

China, another major producer of generic pharmaceuticals, often competes on cost. However, India's stringent regulatory compliance and high number of FDA-approved facilities provide an assurance of quality that is highly regarded in international markets. The European Union, known for its branded generics, typically offers products at higher price points, reflecting brand value and stringent regulatory standards.

In the Dominican Republic, Indian pharmaceutical products are well-accepted, with top buyers such as SAAD MEDICAL and SALDENT INTERNACIONAL S.R.L. sourcing Ampicillin formulations from Indian manufacturers. This indicates a strong track record of supply reliability and regulatory acceptance.

India's pharmaceutical industry has demonstrated robust supply reliability, supported by a vast manufacturing capacity and advanced packaging and cold chain logistics. The country has over 650 U.S. FDA-approved facilities and more than 2,000 WHO-GMP-certified plants as of 2024, ensuring consistent production of high-quality Ampicillin formulations.

Recent years have seen a significant reduction in regulatory non-compliance instances, with U.S. FDA Official Action Indicated (OAI) cases dropping by 50% over the past decade. This improvement underscores the industry's commitment to maintaining high standards.

While specific data on capacity constraints or expansion plans among top Indian Ampicillin formulation manufacturers is limited, the overall growth trajectory of India's pharmaceutical exports suggests a proactive approach to meeting global demand.

For Dominican Republic buyers sourcing Ampicillin formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear communication to understand and negotiate MOQs that align with your procurement needs.

• Payment Terms: Standard payment terms in India-Dominican Republic pharmaceutical trade often include letters of credit (LC) or advance payments. Ensure that agreed terms are documented to avoid misunderstandings.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP), and assessment of quality control systems.

• Regulatory Compliance: Stay updated on both Indian and Dominican Republic regulatory requirements to ensure that imported Ampicillin formulations meet all necessary standards and approvals.

By adopting these strategies, buyers can establish a reliable and efficient sourcing framework for Ampicillin formulations from India.

By adhering to this comprehensive supplier qualification framework, Dominican Republic companies can ensure the procurement of high-quality Ampicillin formulations from Indian manufacturers, safeguarding public health and maintaining regulatory compliance.